CR20220004A - Nuevos compuestos heterocíclicos - Google Patents

Nuevos compuestos heterocíclicos

Info

Publication number
CR20220004A
CR20220004A CR20220004A CR20220004A CR20220004A CR 20220004 A CR20220004 A CR 20220004A CR 20220004 A CR20220004 A CR 20220004A CR 20220004 A CR20220004 A CR 20220004A CR 20220004 A CR20220004 A CR 20220004A
Authority
CR
Costa Rica
Prior art keywords
heterocyclic compounds
new heterocyclic
compounds
sup
new
Prior art date
Application number
CR20220004A
Other languages
English (en)
Inventor
Maurice Biedermann
Benoit Hornsperger
Miroslav Kosar
Flore Reggiani
Fionn O`Hara
Bernd Kuhn
Carsten Kroll
Uwe Grether
Hans Richter
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR20220004A publication Critical patent/CR20220004A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

La invención proporciona nuevos compuestos heterocíclicos que tienen la fórmula general (I): en donde R1 , R2 , X e Y son como se definen en la presente, composiciones que incluyen los compuestos, procesos para fabricar los compuestos y métodos para usar los compuestos.
CR20220004A 2019-07-09 2020-07-07 Nuevos compuestos heterocíclicos CR20220004A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19185088 2019-07-09
PCT/EP2020/069074 WO2021005034A1 (en) 2019-07-09 2020-07-07 New heterocyclic compounds

Publications (1)

Publication Number Publication Date
CR20220004A true CR20220004A (es) 2022-01-31

Family

ID=67220669

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220004A CR20220004A (es) 2019-07-09 2020-07-07 Nuevos compuestos heterocíclicos

Country Status (18)

Country Link
US (1) US20220242876A1 (es)
EP (1) EP3997096A1 (es)
JP (1) JP2022539604A (es)
KR (1) KR20220034104A (es)
CN (1) CN114096545A (es)
AR (1) AR119376A1 (es)
AU (1) AU2020311584A1 (es)
BR (1) BR112021026899A2 (es)
CA (1) CA3145338A1 (es)
CL (1) CL2022000019A1 (es)
CO (1) CO2022000186A2 (es)
CR (1) CR20220004A (es)
IL (1) IL288987A (es)
MX (1) MX2022000243A (es)
PE (1) PE20220515A1 (es)
TW (1) TW202116781A (es)
WO (1) WO2021005034A1 (es)
ZA (1) ZA202110352B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019134985A1 (en) 2018-01-08 2019-07-11 F. Hoffmann-La Roche Ag Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors
EP3837263A1 (en) 2018-08-13 2021-06-23 F. Hoffmann-La Roche AG New heterocyclic compounds as monoacylglycerol lipase inhibitors
EP4028403B1 (en) 2019-09-12 2023-11-22 F. Hoffmann-La Roche AG 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2014110401A (ru) * 2011-08-19 2015-09-27 Мерк Шарп И Доум Корп. Ингибиторы внешнего медуллярного калиевого канала почек
EP2934533B1 (en) * 2012-12-19 2017-11-15 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US10323038B2 (en) * 2015-11-20 2019-06-18 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
BR112019014099A2 (pt) * 2017-01-23 2020-02-11 Pfizer Inc. Compostos espiro-heterocíclico como inibidores de magl
JOP20190267A1 (ar) * 2017-05-23 2019-11-18 Lundbeck La Jolla Research Center Inc مثبطات بيرازول magl

Also Published As

Publication number Publication date
BR112021026899A2 (pt) 2022-05-10
CN114096545A (zh) 2022-02-25
JP2022539604A (ja) 2022-09-12
AU2020311584A1 (en) 2022-01-20
MX2022000243A (es) 2022-02-03
EP3997096A1 (en) 2022-05-18
KR20220034104A (ko) 2022-03-17
PE20220515A1 (es) 2022-04-07
IL288987A (en) 2022-02-01
TW202116781A (zh) 2021-05-01
AR119376A1 (es) 2021-12-15
CO2022000186A2 (es) 2022-01-17
US20220242876A1 (en) 2022-08-04
WO2021005034A1 (en) 2021-01-14
ZA202110352B (en) 2022-08-31
CL2022000019A1 (es) 2022-10-21
CA3145338A1 (en) 2021-01-14

Similar Documents

Publication Publication Date Title
CR20210247A (es) Nuevos compuestos heterocíclicos
MX2021001433A (es) Nuevos compuestos heterociclicos como inhibidores de la monoacilglicerol lipasa.
WO2020243415A3 (en) Tead inhibitors and uses thereof
CR20210056A (es) Nuevos compuestos heterocíclicos como inhibidores de monoacilglicerol lipasa
MX2020008894A (es) Inhibidores de oxazin monoacilglicerol lipasa (magl).
MX2021014441A (es) Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
MX2021002978A (es) Lactamas biciclicas y metodos de uso de las mismas.
CR20220116A (es) Compuestos heterocíclicos
CR20220118A (es) Nuevos inhibidores heterocíclicos de monoacilglicerol lipasa (magl)
CR20220004A (es) Nuevos compuestos heterocíclicos
MX2021014350A (es) Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de los mismos y metodos de tratamiento con los mismos.
MX2022002831A (es) Compuestos heterociclicos.
CR20230496A (es) Compuestos heterocíclicos
MX2023002224A (es) Compuestos heterociclicos.
MX2020002449A (es) Nuevos compuestos heterociclicos fungicidas.
MX2020013630A (es) Analogos de rapamicina y usos de los mismos.
WO2018035346A8 (en) KINASE INHIBITING COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING CANCER
MX2022002554A (es) Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de monoacilglicerol lipasa (magl).
MX2020006370A (es) Pirazolopiridina-diamidas, su uso como insecticida y procesos para prepararlas.
CR20230382A (es) Derivados de tetrahidroazepina bicíclicos para el tratamiento del cáncer
CR20230410A (es) Derivados novedosos de pirimidin-2-il-sulfonamida
MX2021001904A (es) Formas solidas de benzoxaborol sustituido y composiciones de las mismas.
WO2018166993A3 (en) PYRAZOLOCHLOROPHENYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
MX2020013518A (es) Nuevos derivados de isoxazolil eter como moduladores alostericos positivos (pam) del receptor de acido gamma-aminobutirico a alfa5 (gaba a alfa5).
MX2021015480A (es) Compuestos heterociclicos fusionados y su uso como agentes de control de plagas.